Biodefense and Infectious Disease
As a leading provider of infectious disease contract research services, our Molecular and Microbiology Division offers a wide range of studies for the development of new vaccines or medical countermeasures (MCMs) including the evaluating the immunogenicity, efficacy, potency, and safety of vaccines, antitoxins and therapeutics. IITRI has extensive experience in the development of vaccines against emerging infectious diseases such as Zika virus, influenza, antibiotic resistant bacteria (i.e., superbugs) or respiratory syncytial virus (RSV), which continue to pose a threat to public health both in the US and abroad. We are also highly experienced in handling bacterial or viral infectious agents that are potential bioterrorism agents when aerosolized, such as Bacillus anthracis (anthrax) and Yersinia pestis (plague), in animal challenge studies.
We offer an extensive collection of infectious disease animal models including influenza ferret models that are available for efficacy testing of therapeutic antibiotics or antivirals and vaccines, including small molecules and biologics. IITRI also offers complete GLP-compliant preclinical vaccine toxicology programs and Animal Rule studies. We are one of the very few labs in the US that offers GLP-compliant BSL-2 and BSL-3 facilities for infectious disease preclinical studies using select agents.
Our laboratory and vivarium space includes Biosafety Level 2 and 3+ facilities, fully functional with the latest equipment to conduct pathogenic agent studies. We are registered with the CDC and USDA for possession and use of select agents and toxins. Our BSL-3 lab houses our bioaerosol generation and aerosol exposure system for inhalation delivery of pathogens or antiinfective treatments for viral or bacterial aerosol challenge studies and therapeutic efficacy studies for antibiotics or antivirals.